Lipid-poor adrenal adenoma versus metastasis in lung cancer: Diagnosis by “comparative enhancement” at multiphasic MR imaging

Sir,

Lung cancer spreads frequently to the adrenal gland;\(^1\,^2\) at this side, the prevalence of an incidental lesion ranges from 0.4%–5% of radiologic studies by computed tomography (CT) imaging.\(^3\,^4\)

Although in the setting of oncologic patients, the term “incidentaloma” may not be appropriate, a tremendously discovered adrenal lesion by radiologic studies in the 20% of the cases is a probable metastasis.\(^4\) The increase in the prevalence of incidentally adrenal masses is parallel to the ample use of imaging and represents a clinical problem;\(^5\) in addition, the imaging procedures have a fundamental role to establish the nature of very unusual lesions in other sites.\(^6\,^7\)

In daily clinical practice, in patients with lung cancer, the differentiation by imaging of a small (2–3 cm) incidental nonfunctioning adrenal nodule from metastasis is crucial in the treatment decision-making. Particularly, the main diagnostic challenge is to differentiate lipid-poor adenoma from metastasis.\(^8\)

The abundance of lipids in the adrenal adenoma determines attenuation values of <10 HU and is suggestive of a benign adenoma at CT.\(^9\) Conversely, in the lipid-poor adenomas (10%–40% of all adrenal adenomas),\(^10\) similarly to the metastasis, the lipids are scarce, higher attenuation values are revealed at CT and may be indistinguishable from malignancy.\(^11\) Calculation of contrast washout rate by CT allows the diagnosis of lipid-poor adenoma; however, this methodology is not always possible: many CT examinations do not undergo unenhanced or delayed (15 min) contrast-enhanced CT.

Magnetic resonance (MR) imaging is equivalent to CT for characterizing adenomas measuring 20 HU or less. MR imaging is less sensitive than CT for lipid-poor adenomas measuring > 20 HU.\(^12\) The accuracy of the MR imaging in diagnosis of lipid-poor cortical adrenal adenoma is of 91.3%–93.5%.\(^13\) On diffusion-weighted MR imaging, the adenomas similarly to the adrenal metastasis demonstrate restricted diffusion.\(^14\)

Incidental non-functioning adenoma is a circumscribed expansile of the adrenal cortex with a similar structure to that of normal tissue of the adrenal cortical gland in terms of vascularization and amount of lipid droplets (lipid-rich and lipid-poor).\(^15\)

Based on this histopathologic data, we believe that the “comparative enhancement” at multiphasic MR imaging can be a reliable method to determine the vascularization of the normal adrenal cortex and to distinguish lipid-poor adenoma from metastasis when a nodule is revealed in patients with lung cancer.

Comparative enhancement represents an innovative approach for the quali-quantitative assessment of the vascularization of the normal adrenal cortex contralaterally or ipsilaterally to the adrenal cortical nodule. The quantitative analysis of enhancement is performed positioning a circular region-of-interest into a magnified image of adrenal gland (contralaterally or ipsilaterally to the adrenal nodule) and into a homogeneous area of the adrenal nodule on unenhanced and in post-contrast arterial, venous and delayed (5 min) phase MR imaging. Time-signal intensity curve (TIC) from multiphasic MR imaging for normal adrenal gland and adrenal lesion is determined, and the patterns of TIC.
We retrospectively analyzed the multiphasic MR imaging at 1.5 T and 3 T of 24 patients with nonenlarged, normal adrenal gland and of 17 patients with lung cancer in which a small (≤3 cm) incidentaloma (lipid-poor adenoma \( n = 8 \) and metastases \( n = 9 \)) was detected and confirmed by histology or follow-up imaging. Our preliminary results demonstrated that normal adrenal gland contralaterally or ipsilaterally to the adrenal cortical nodule exhibits similar profile of TIC in comparison to lipid-poor adenoma (TIC with a maximum peak in arterial phase followed by a decline) [Figure 1] and different to progressive and persistent TIC of metastasis [Figure 2].

Our preliminary results demonstrate that in clinical practice, comparative enhancement is a reliable and effective tool for differentiating lipid-poor adenoma from metastasis in patients with lung cancer.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Michele Scialpi, Alfredo D’Andrea, Valeria Rondoni, Emanuele Orlandi, Serena Bernardini, Maria Napoletano, Teresa Pusio

Department of Surgical and Biomedical Sciences, Division of Radiology 2, S.M. Della Misericordia Hospital, Perugia, 1Department of Sperimental Medicine, Magrassi Lanzara, Luigi Vanvitelli, Second University of Naples, Naples, 2Provincial Health Care, Institute of Anatomic Pathology, Rovereto Hospital, Rovereto, Italy

E-mail: michelescialpi1@gmail.com

REFERENCES

1. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung
Letters to Editor

Cancer 2014;86:79-84.
2. Bazhenova L, Newton P, Mason J, Bethel K, Niew J, Kuhn P, et al. Adrenal metastases in lung cancer: Clinical implications of a mathematical model. J Thorac Oncol 2014;9:442-6.
3. Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berotti A, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006;29:298-302.
4. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003;149:273-85.
5. Grifflng GT. A±D-S: The new endocrine epidemic. J Clin Endocrinol Metab 1994;79:1530-1.
6. Pusiol T, Scialpi M. Role of computed tomography in the preoperative diagnosis of giant benign solitary fibrous tumor pleura. Lung India 2013;30:82-5.
7. Roncati L, Pusiol T, Scialpi M. The endothoracic fascia: An anatomic site in which primary liposarcoma may arise. Lung 2015;193:1055-6.
8. Szolar DH, Korobkin M, Reitnner P, Berghold A, Baumhofer T, Trummer H, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: Mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005;234:479-85.
9. Ilias I, Sahdev A, Reznik RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: A comparison of different methods. Endocr Relat Cancer 2007;14:587-99.
10. Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: Pathologic conditions, pearls, and pitfalls. Radiographics 2009;29:1333-51.
11. Kapoor A, Morris T, Rebecco R. Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J 2011;5:241-7.
12. Seo JM, Park BK, Park SY, Kim CK. Characterization of lipid-poor adrenal adenoma: Chemical-shift MRI and washout CT. AJR Am J Roentgenol 2014;202:1043-50.
13. Becker-Weidman D, Kalb B, Mittal PK, Harri PA, Arif-Tiwari H, Farris AB 3rd, et al. Differentiation of lipid-poor adrenal adenomas from non-adenomas with MR imaging: Utility of dynamic, contrast enhancement and single-shot T2-weighted sequences. Eur J Radiol 2015;84:2045-51.
14. Blake MA, Holalkere NS, Boland GW. Imaging techniques for adrenal lesion characterization. Radiol Clin North Am 2008;46:65-78, vi.
15. Lack EE. Adrenal cortical adenoma. In: Tumors of the Adrenal Glands and Extraadrenal Paraganglia by EE Lack AFIP Atlas of Tumor Pathology. 4th Series Fascicle 8. Washington, DC: Armed Forces Institute of Pathology; 2007. p. 99.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online

How to cite this article: Scialpi M, D'Andrea A, Rondoni V, Orlandi E, Bernardini S, Napoletano M, et al. Lipid-poor adrenal adenoma versus metastasis in lung cancer: Diagnosis by “comparative enhancement” at multiphasic MR imaging. Lung India 2018;35:364-6.

© 2018 Indian Chest Society | Published by Wolters Kluwer - Medknow